MacroGenics
Business Services · Maryland, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
9704 Medical Center Dr, Rockville, Maryl...Phone Number
(301) 251-5172Website
www.macrogenics.comRevenue
$157.1 MillionStock Symbol
MGNXIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
2
2
2
2
About MacroGenics
MacroGenics, Inc. is a publicly traded biotechnology company dedicated to discovering, developing, manufacturing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The organization specializes in immuno-oncology and applies proprietary antibody engineering technologies to create medicines that enhance the immune system's ability to recognize and eliminate cancer cells. By integrating scientific research, translational medicine, clinical development, and biologics manufacturing, the company seeks to address significant unmet medical needs across multiple oncology indications.Explore more
MacroGenics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MacroGenics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at MacroGenics
Check out if MacroGenics is spiking on competitors!
Click to see if MacroGenics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once MacroGenics has new funding data
MacroGenics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on MacroGenics recently announced quarterly report
Check if MacroGenics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when MacroGenics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined MacroGenics as Masked Content
Find more new buyers
Compare Similar Companies to MacroGenics
Compare insights from companies similar to MacroGenics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$105M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
MacroGenics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MacroGenics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MacroGenics.
MacroGenics financials insights
Gather financial insights about MacroGenics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Series D
$25M
2010
Grant
$9.8M
2013
Stock Offering
$83.8M
2014
Stock Offering
$76.7M
2015
Stock Offering
$141M
2017
Stock Offering
$23.6M
2018
Stock Offering
$110M
MacroGenics Tech Stack
A closer look at the technologies used by MacroGenics
See more technologies
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Mergers & Acquisitions (M&A)
Divestiture
Divestitures
Open Position
Person-Based
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
MacroGenics News & Media
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended June 30, 2026, and highlighted its recent corporate and pipeline progress.MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies’ 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics.MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug conjugate (ADC), incorporating a topoisomerase I inhibitor-based linker-payload, in patients with advanced solid tumors. MacroGenics plans to present dose escalation and prelMacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced completion of the sale of MacroGenics’ good manufacturing practice (GMP) drug substance manufacturing operations to Bora.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MacroGenics
Sign Up For FreeTo access detailed company insights
MacroGenics, Inc. is a publicly traded biotechnology company dedicated to discovering, developing, manufacturing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The organization specializes in immuno-oncology and applies proprietary antibody engineering technologies to create medicines that enhance the immun... Read More
